Sacituzumab Tirumotecan Plus Pembrolizumab Shows Superiority in PD-L1–Negative NSCLC

Results from the randomized Phase III OptiTROP-Lung06 trial, presented at the ESMO Congress 2026, indicate that sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab significantly reduced the risk of progression or death by 51% compared to pembrolizumab plus platinum-pemetrexed chemotherapy in patients with PD-L1-negative advanced non-squamous non-small cell lung cancer (NSCLC). The median progression-free survival reached 15.0 months with the sac-TMT combination versus 5.7 months with chemoimmunotherapy.